Off-Label Use of Atypical Antipsychotics: An Update
Results: Atypical Antipsychotics for Obsessive-Compulsive Disorder
Atypical antipsychotics have been used to treat obsessive-compulsive disorder as augmentation of selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors. In comparisons with placebo for response rate measured with the YBOCS in 3 trials with a total of 97 subjects, risperidone resulted in 1 of every 5 patients demonstrating an improved YBOCS score. The strength of evidence for this finding is moderate.
In head-to-head trials of comparative effectiveness, olanzapine was compared with risperidone in 1 trial of 50 participants by using the YBOCS score. No statistically significant difference between treatments was detected. The strength of evidence for this finding is low.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | obsessive-compulsive | OCD | SSRI | SNRI | risperidone | quetiapine | risperidone | ziprasidone | clomipramine | olanzapine | YBOCS
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.